anti-CLDN18.2/PD-L1 CAR-T cell therapy (Sichuan University)

N/A

Report date: 2025/06/11 10:34:44

Base Information

Drug Nameanti-CLDN18.2/PD-L1 CAR-T cell therapy (Sichuan University)
Drug Alias Namedual-targeting CLDN18.2 and PD-L1 CAR-T cells (Sichuan University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT lymphocytes stimulantsClaudin 18 protein modulatorsProgrammed death-ligand 1 modulators +[4] 
TargetsClaudin-18 splice variant 2Programmed death-ligand 1
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A